查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1487659

外用抗生素市場 - 按藥物類別、劑型、產品類型、藥物類型、應用、配銷通路、全球預測 2024 - 2032 年

Topical Antibiotics Market - By Drug Class, Dosage Form, Product Type, Medication Type, Application, Distribution Channel, Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於細菌和真菌感染等皮膚感染盛行率不斷上升，預計 2024 年至 2032 年外用抗生素市場規模的複合年成長率將達到 5.4%。糖尿病足潰瘍和壓瘡等慢性傷口的發生率不斷上升，促使人們採用外用抗生素來治療傷口和預防感染。根據著名醫學雜誌《JAMA》報道，每年，糖尿病足潰瘍影響全球約1860 萬人，其中約160 萬例發生在美國。將刺激人們對感染控制措施的重視。

製造商正在進一步開發創新配方，例如霜劑、軟膏、凝膠和噴霧劑，以提高滲透性和持續釋放特性，以最佳化藥物傳輸並提高患者依從性。美容皮膚科擴大採用外用抗生素來治療痤瘡和其他皮膚病，加上消費者對非處方外用抗生素產品的需求不斷成長，將有助於市場的擴張。

外用抗生素產業分為藥品類別、劑型、產品類型、用藥類型、應用、配銷通路和地區。

到 2032 年，學名藥產品類型細分市場的市場規模預計將實現 5.9% 的複合年成長率。通用外用抗生素的可近性和可負擔性使其對醫療保健提供者和患者更具吸引力。學名藥製造商也投資研發活動，以創造生物等效製劑，以確保與品牌製劑具有可比性的功效和安全性。

眼部感染應用領域的局部抗生素市佔率預計在 2024 年至 2032 年期間將成長 5.5%。眼部感染，例如結膜炎和角膜炎，是由細菌或真菌病原體引起的常見眼部疾病，需要及時有效地使用局部抗生素進行治療。與不良衛生習慣、隱形眼鏡使用和環境因素相關的眼部感染盛行率不斷上升，將增加對局部抗生素作為主要治療介入的需求。

由於人口密度高和熱帶氣候為細菌和真菌感染的傳播創造了有利的環境，預計到 2032 年，亞太地區外用抗生素產業將獲得動力並以 5.8% 的複合年成長率成長。在亞太地區人口稠密的城市地區和農村社區，結膜炎、膿皰病和皮膚真菌感染等傳染病的發生率正在增加。中國、印度和東南亞國家等國家不斷擴大的醫療基礎設施和不斷成長的可支配收入將推動外用抗生素的可及性，進一步推動區域市場的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 皮膚感染的發生率增加
      • 抗生素抗藥性上升
      • 擴大配方的進步
      • 不斷增加的監管支持
    • 產業陷阱與挑戰
      • 不良反應和安全問題
      • 偏好全身抗生素
  • 成長潛力分析
  • 管道分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2018 - 2032 年

  • 主要趨勢
  • 四環素
  • 氨基糖苷類
  • 紅黴素
  • 克林黴素
  • 其他藥物類別

第 6 章：市場估計與預測：按劑型，2018 - 2032 年

  • 主要趨勢
  • 藥膏
  • 乳霜
  • 解決方案
  • 粉末
  • 其他劑型

第 7 章：市場估計與預測：按產品類型，2018 年 - 2032 年

  • 主要趨勢
  • 品牌化
  • 泛型

第 8 章：市場估計與預測：按藥物類型，2018 - 2032 年

  • 主要趨勢
  • 場外交易 (OTC)
  • 處方

第 9 章：市場估計與預測：按應用分類，2018 年 - 2032 年

  • 主要趨勢
  • 皮膚感染
  • 眼部感染
  • 耳部感染
  • 鼻腔感染
  • 其他應用

第 10 章：市場估計與預測：按配銷通路分類，2018 年 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局和藥局
  • 網路藥局

第 11 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要動向：按地區
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 12 章：公司簡介

  • Almirall S.A.
  • Bausch Health Companies Inc.
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Consumer Inc.
  • Lupin
  • Medimetriks Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Mayne Pharma Group Limited.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
簡介目錄
Product Code: 8570

Topical antibiotics market size is predicted to witness 5.4% CAGR from 2024 to 2032, driven by the increasing prevalence of skin infections, including bacterial and fungal infections. The rising incidence of chronic wounds, such as diabetic foot ulcers and pressure ulcers is driving the adoption of topical antibiotics for wound management and infection prevention. As per well-known medical journal JAMA, every year, diabetic foot ulcers impact roughly 18.6 million individuals globally, with approximately 1.6 million cases occurring in the U.S. The growing awareness about the importance of infection control measures, particularly in healthcare settings, will stimulate the demand for topical antibiotics for the treatment and prevention of healthcare-associated infections.

Manufacturers are further developing innovative formulations, such as creams, ointments, gels, and sprays, with improved penetration and sustained release properties for optimizing drug delivery and enhancing patient compliance. The increasing adoption of topical antibiotics in cosmetic dermatology for the treatment of acne and other skin conditions, coupled with the rising consumer demand for OTC topical antibiotic products will contribute to the market expansion.

The topical antibiotics industry is divided into drug class, dosage form, product type, medication type, application, distribution channel, and region.

The market size from the generics product type segment is set to witness 5.9% CAGR up to 2032. As patents for branded topical antibiotics expire, generic versions have become available, leading to increased competition and lower prices. This accessibility and affordability of generic topical antibiotics makes them more attractive to healthcare providers and patients. Generic manufacturers are also investing in R&D activities to create bioequivalent formulations for ensuring comparable efficacy and safety to their branded counterparts.

Topical antibiotics market share from the eye infection application segment is anticipated to observe 5.5% growth rate during 2024-2032. Eye infections, such as conjunctivitis and keratitis, are common ocular conditions caused by bacterial or fungal pathogens, necessitating prompt and effective treatment with topical antibiotics. The increasing prevalence of eye infections, associated to poor hygiene practices, contact lens use, and environmental factors will contribute to the demand for topical antibiotics as the primary therapeutic intervention.

Asia Pacific topical antibiotics industry is anticipated to gain momentum and grow at a 5.8% CAGR through 2032, attributed to the high population density and tropical climate that creates conducive environments for the spread of bacterial and fungal infections. The incidence of infectious diseases, such as conjunctivitis, impetigo, and fungal skin infections, in densely populated urban areas and rural communities across APAC is increasing. The expanding healthcare infrastructure and the rising disposable incomes in countries like China, India, and Southeast Asian nations will fuel the accessibility of topical antibiotics, further driving the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of skin infections
      • 3.2.1.2 Rising antibiotic resistance
      • 3.2.1.3 Expanding advancements in formulations
      • 3.2.1.4 Growing regulatory support
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects and safety concerns
      • 3.2.2.2 Preference for systemic antibiotics
  • 3.3 Growth potential analysis
  • 3.4 Pipeline analysis
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tetracycline
  • 5.3 Aminoglycoside
  • 5.4 Erythromycin
  • 5.5 Clindamycin
  • 5.6 Other drug classes

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Ointments
  • 6.3 Creams
  • 6.4 Solutions
  • 6.5 Powders
  • 6.6 Other dosage forms

Chapter 7 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Branded
  • 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Medication Type, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Over-the-counter (OTC)
  • 8.3 Prescription

Chapter 9 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Skin infection
  • 9.3 Eye infection
  • 9.4 Ear infection
  • 9.5 Nasal infections
  • 9.6 Other applications

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Hospital pharmacies
  • 10.3 Retail pharmacies & drug stores
  • 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 11.1 Key trends, by region
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 Rest of Asia Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 Rest of Middle East and Africa

Chapter 12 Company Profiles

  • 12.1 Almirall S.A.
  • 12.2 Bausch Health Companies Inc.
  • 12.3 Bayer AG
  • 12.4 GlaxoSmithKline plc
  • 12.5 Johnson & Johnson Consumer Inc.
  • 12.6 Lupin
  • 12.7 Medimetriks Pharmaceuticals Inc.
  • 12.8 Merck & Co., Inc.
  • 12.9 Mayne Pharma Group Limited.
  • 12.10 Novartis AG
  • 12.11 Pfizer Inc.
  • 12.12 Sanofi
  • 12.13 Sun Pharmaceutical Industries Ltd.
  • 12.14 Teva Pharmaceutical Industries Ltd.
  • 12.15 Viatris Inc.